After the regulator’s rejection of two rivals, GlaxoSmithKline’s daprodustat could be the first in a new class of oral anemia drugs approved in the US, but concerns about class safety may mean its use is limited.
The company confirmed on 19 April that the US Food and Drug Administration had accepted the filing of the oral...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
